‘Uber for drones’: Aerologix capital raise, acquisition to lift global reach
Australian drone technology start-up Aerologix will use a fresh capital injection to escalate its aggressive global expansion and to launch a new mapping solution.
Australian drone technology start-up Aerologix will use a fresh capital injection to escalate its aggressive global expansion and to launch a new mapping solution.
The NASDAQ hosts premier tech stocks like Netflix, Apple, Alphabet, Meta, Microsoft, and Nvidia, but Tiger Brokers says plenty of others are popular with Aussie investors.
Combining the work of Sir Isaac Newton and these three metrics adds up to valuable opportunities for a special class of ASX investor.
Clinuvel Pharmaceuticals and ANZ have been under brokers’ microscopes. One has been given a series of ticks, the other … not so much.
These two stocks may deal with cannabis but are determined to be much more than ‘pot peddlers’, as they rely on innovation and medical rigour to forge new paths.
Copper’s performance has been a underwhelming of late. But these nine undervalued ASX stocks are preparing for a seemingly inevitable recovery.
Strange day for ASX resources stocks, with plenty of gains, including MinRex’s early 50 per cent jump, on not much new information.
Good news and bad news for health stocks. Singular Health pumped after securing funds, while a possible tax debt hit Pacific Smiles Group.
Renowned global mining and trading house Glencore has thrown its weight behind Galan Lithium’s Hombre Muerto West project, with an offtake and funding deal.
Impact boss Dr Mike Jones is great at mining and rocks. But when it comes to ESG, he’s happy for a little help. Enter, Socialsuite.
The Secret Broker was trying to discover Man of Steel Sanjeev Gupta’s net worth. Easy enough you’d think but not so. Even AI was no help.
Investors looking for takeover action in 2024 should note a growing hunger in the small-cap financial advisory sector, says Tim Boreham.
Lithium project developers often suffer capex blowouts but not Vulcan, which now expects lower start-up costs at its Zero Carbon Lithium project, with the same production capacity.
Antilles Gold has intersected high grade copper – including a top hit of 11m grading 4.7 per cent copper – at the El Pilar copper-gold porphyry deposit in central Cuba.
Oil prices have slid a little over recent weeks, which is good news for Aussie consumers. And so is the rise of renewable energy in the eastern states.
Getting a mining project off the ground these days can be a tough test. Resources investment house Argonaut reckons these 11 are most likely to pass.
Panoramic Resources has commissioned a strategic review that could result in a complete or partial sale of its flagship Savannah nickel mine in WA.
Two lithium stocks are riding an exhilarating wave on Thursday, with one up more than 50 per cent, and the other jumping 44 per cent.
With rare earths elements prices switching up a gear, these ASX companies are tackling the sometimes difficult and expensive quest to mine them.
Uvre has staked the South Pass hard rock lithium project in Wyoming at a time when the US government is actively funding domestic sources of strategic minerals.
The Andover project looks an absolute giant after another flurry of assay results confirmed Target Area 3 as one of Azure Minerals’ ‘highest ranked lithium target’”.
CSIRO-led modelling has revealed major extensions to rare earths basins within OD6 Metals’ intriguing Splinter Rock project near Esperance, WA.
Argenica Therapeutics has achieved a key milestone, with the US FDA granting orphan drug designation for ARG-007 for the treatment of hypoxic ischaemic encephalopathy.
Bond yields are showing signs of fatigue, says senior analyst Kyle Rodda. And he has nominated three ASX stocks with a history of shining in this scenario.
Good neighbours never go astray, and Errawarra Resources has some corkers close to its Andover West project. So it’s no surprise ERW has been surging.
Amid industry experts’ dire warnings of a looming copper supply deficit, these ASX stocks are putting in the hard yards to bring new projects online.
Embattled ASX coking coal producer MC Mining is up 50 per cent after two of its largest shareholders launched a takeover bid. Here’s your resources wrap.
Great news for two ASX biotechs, with Neuren Pharma almost tripling its DAYBUE sales in a quarter and Argenica’s shares soaring by 40 per cent.
Corella Resources has unleashed a monstrous scoping study highlighting two highly attractive development scenarios for its Tampu alumina project in WA.
October wasn’t hugely strong for junior resource companies, but a few muscled up big time and are entering November looking pretty buff.
As lithium prices slump and a gloomy EV demand outlook emerges, many are bearish on battery metals. But two industry leaders beg to differ.
Alvo Minerals has ridden good news about its Brazilian Bluebush project to a 28 per cent gain for the day. Here’s your ASX resources wrap.
Island Pharmaceuticals aims to guard against mosquito-borne diseases – and now it has more protection itself, with a key patent granted. Get your health news here.
Guru Bernard Marr has predicted the factors that will drive the healthcare sector in 2024. But no need to wait – these ASX stocks are already in high gear.
MGC Pharmaceuticals has secured almost $US8 million in a capital raise to support its business plan, including its focus on FDA IND applications for CimetrA and CannEpil.
Melodiol Global Health subsidiary Mernova Medicinal achieved record revenue of nearly $900k in October with purchase orders over $600k already for November.
With traditional energy sources hit by volatility, these ASX resource players are embracing renewables to save money and help clean up the industry’s image.
The world is on course for a swing towards green steel, and that means higher-grade ore. These ASX stocks are helping drive that transition.
One of 2023’s best performing gold miners – Cambodia-focused Emerald Resources – has crystallised an outsized gain this year to charge into the ASX 200.
Pharmaceutical manufacturer IDT Australia has surged on strong results. Meanwhile, Paradigm Biopharma emerged from a trading halt, only to plummet.
The canny investor keeps an eye on drilling programs, given it’s said that resource explorers live or die by the drill bit. These are set to take centre stage.
Soft tissue repair company Aroa Biosurgery is focused on building its product offering, gaining a foothold in key markets, and transitioning to a high-profitability business.
The vast promise of mRNA vaccines is limited by the spectre of inflammatory reactions. But an ASX firm is tackling that issue – and one of the most deadly cancers.
In the race to satisfy the EV market’s accelerating need for manganese, these ASX explorers are heading in opposite directions.
Nickel Industries says Western vehicle makers are starting to realise they’re going to need Indonesian supply, despite the protestations of its peers.
Copper, lithium and REEs hunter Encounter Resources has lived up to its name – finding niobium-REE carbonatites in WA. Here’s your resources wrap.
A widely anticipated scoping study shows Lithium Energy’s 3.3Mt Solaroz lithium brine project will take just 2-2.5 years to pay back development costs, once in production.
Chimeric Therapeutics made a huge surge after the US Food and Drug Administration threw its support behind a new cancer-fighting drug.
Samples from the 560m-long Warhawk pegmatite at James Bay Minerals’ Aero tenure have returned lithium concentrations containing spodumene crystals, confirming its prospectivity.
Morningstar says property group Abacus faces some headwinds, but still rates it a Buy, with a ‘fair value’ 82 per cent higher than its current price.
Original URL: https://www.heraldsun.com.au/business/stockhead/page/48